The specific and significant COVID-19 risk of ADE... should be prominently and independently disclosed to...future patients after vaccine approval, in order to meet the medical ethics standard of patient comprehension for informed consent.https://t.co/x22wm7J3hV— Giovanna Cordinglese (@GCordinglese) August 17, 2021
Sure, along with the fact that the primary risk for ADE lies in the nucleocapsid antigen, which is not selected by any vaccine offered in the United States of America.
It should be disclosed that the greatest risk for ADE is with infection. So says the 2012 SARS paper on the subject, which did extensive research specifically on the risk of ADE in SARS-CoV-1.